Skip to main content
. 2021 Sep 14;12(19):1920–1936. doi: 10.18632/oncotarget.28068

Figure 4. Proliferation analysis of tumor sections.

Figure 4

(A) Tumor sections from the different experimental groups administered intraperitoneally (i.p.) with: Vehicle, 4bt (80 mg/Kg), 4bc (80 mg/Kg), paclitaxel (20 mg/Kg), Doxorubicin (10 mg/Kg) + Cyclophosphamide (100 mg/Kg) followed by paclitaxel (10 mg/Kg) (AC-T) and Doxorubicin (10 mg/Kg) + Cyclophosphamide (100 mg/Kg) followed by KIF11 inhibitor 4bt (AC-4bt) were immunostained for Ki67 (green) and genetic material (blue). (B) Percentage of Ki67 positive nuclei for each experimental group. Data represent mean ± SEM of three independent experiments. ** p < 0.01, **** p < 0.0001 as compared to control group (vehicle). Bars: 25 μm.